-

CEO, Jakob Lindberg, will attend the Nordic Life Science Days, 14-15 September 2016 in Stockholm Sweden.

Oncopeptides presented clinical results from a Phase 2 study of melflufen and dexamethasone in patients with relapsed-refractory multiple myeloma at the 21th European Hematology Association Congress in Copenhagen, Denmark, June 7 – 11.

The results can be downloaded below.

The results further support Oncopeptides’ belief that melflufen has the potential to make a meaningful difference in the lives of patients with relapsed-refractory multiple myeloma, providing a reliable go-to alternative even when conventional therapies have failed”.

For further information or to arrange a meeting for discussions please contact Jakob Lindberg (CEO) or Björn Hammarberg (BD).

Upcoming events

Carnegie Healthcare Conference

-

47th Annual Meeting of the EBMT

-

The European Society for Blood and Marrow Transplantation 2021.

AACR Annual Meeting 2021

-

Virtual Meeting Week 1: April 10-15; Week 2: May 17-21

European School of Haematology E-conference 2021

-

E-Conference - How to Diagnose and Treat Multiple Myeloma.

COMy 2021

-

World Congress on Controversies in Multiple Myeloma 2021.

ASCO 2021 Annual Meeting

-

American Society of Clinical Oncology (ASCO) 2021.

EHA 2021 Virtual Congress

-

European Hematology Association Annual meeting 2021.

Interim Report Q2 2021

08:00 CET

Interim Report Q3 2021

08:00 CET